Denosumab (Xgeva)

Provider Name (print)

Provider Order Form rev. 01/03/2024

PATIENT INFORMATION	Referral Status: □ New Referral □ Updated Order □ Order Renewal
Patient Name:	DOB: Patient Phone:
Patient Address:	Patient Email:
Allergies:	☐ NKDA Weight (lbs/kg): Height (in/cm):
Sex: ☐ M / ☐ F Date of Last Infusion:	Next Due Date: Preferred Location:
DIAGNOSIS (Please provide ICD-10 code in space	provided)
Post-menopausal osteoporosis:	Bone metastasis, Associated with solid tumors:
Multiple myeloma:	Giant cell tumor of bone:
Hypercalcemia of malignancy, Refractory to bisphos	sphonates:
Other: Descrip	otion:
REQUIRED INFORMATION ☑ Current calcium level	PRE-MEDICATION ORDERS ☐ Other:
THERAPY ADMINISTRATION (Choose one)	LABORATORY ORDERS
☐ Multiple myeloma/bone metastasis from solid tur Administer denosumab (Xgeva) 120mg subcutaneousl	
weeks. Giant cell tumor of bone/hypercalcemia of malign Administer denosumab (Xgeva) 120mg sub-q every 4 vadditional doses on day 8 and day 15 of the first mont treatment. Hypercalcemia of Malignancy: Administer denosur 120mg subcutaneously every 4 weeks with additional subcutaneously doses at Day 8 and 15 of the first montherapy. ADDITIONAL ORDERS	weeks with h of Hold infusion and notify provider for: Hypercalcemia or hypocalcemia Patient is also on Prolia. Jaw mouth or tooth pain following treatments/Thigh, hip or groin pain/fractures of the femur or vertebra Suspected pregnancy
PROVIDER INFORMATION	
Preferred Contact Name:	Preferred Contact Email:
Ordering Provider:	Provider NPI: Phone: Fax:
Referring Practice Name: Practice Address:	Phone: Fax: City: State: Zip Code:
	Additional documentation required for processing and insurance approval) front and back of primary and secondary insurance, 2 most recent OVN including
•	phates, Reclast, Prolia, Evenity. History of GERD, fractures, T score

Date

Provider Signature